Physician profile
Daksha Patel
NPI 1972834976
$396.91
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2020: $85.56.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $76.40 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $62.59 | 2019 | |
| Sarepta Therapeutics, INC. | $41.29 | 2019 | |
| Sanofi Pasteur INC. | $37.63 | 2019-2020 | |
| Abbott Laboratories | $36.20 | 2020 | |
| Nevro Corp. | $28.46 | 2019 | |
| Amgen INC. | $21.89 | 2019 | |
| Merck Sharp & Dohme LLC | $19.08 | 2019 | |
| Allergan, INC. | $17.42 | 2020 | |
| Philips North America LLC | $17.35 | 2019 | |
| Lilly USA, LLC | $13.76 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.69 | 2019 | |
| Pfizer INC. | $11.15 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daksha Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.